Tonghua Dongbao Pharmaceutical Co Ltd
Tonghua Dongbao Pharmaceutical Co., Ltd. researches, develops, produces, and markets pharmaceuticals in China. It offers human insulin injections; insulin glargine injections; insulin aspart injections; liraglutide injections; and proprietary Chinese medicine. The company also provides insulin pen and pen needles; and chronic disease management platform, a diabetes management platform for drug tr… Read more
Tonghua Dongbao Pharmaceutical Co Ltd (600867) - Total Assets
Latest total assets as of September 2025: CN¥8.15 Billion CNY
Based on the latest financial reports, Tonghua Dongbao Pharmaceutical Co Ltd (600867) holds total assets worth CN¥8.15 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Tonghua Dongbao Pharmaceutical Co Ltd - Total Assets Trend (1994–2024)
This chart illustrates how Tonghua Dongbao Pharmaceutical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Tonghua Dongbao Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Tonghua Dongbao Pharmaceutical Co Ltd's total assets of CN¥8.15 Billion consist of 27.2% current assets and 72.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.0% |
| Accounts Receivable | CN¥569.45 Million | 7.7% |
| Inventory | CN¥736.31 Million | 10.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.64 Billion | 22.3% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (1994–2024)
This chart illustrates how Tonghua Dongbao Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tonghua Dongbao Pharmaceutical Co Ltd's current assets represent 27.2% of total assets in 2024, a decrease from 77.1% in 1994.
- Cash Position: Cash and equivalents constituted 8.0% of total assets in 2024, up from 0.0% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 0.0% in 1994.
- Asset Diversification: The largest asset category is intangible assets at 22.3% of total assets.
Tonghua Dongbao Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Tonghua Dongbao Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Tonghua Dongbao Pharmaceutical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Tonghua Dongbao Pharmaceutical Co Ltd generates 0.27x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Tonghua Dongbao Pharmaceutical Co Ltd is currently not profitable relative to its asset base.
Tonghua Dongbao Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.64 | 4.30 | 9.23 |
| Quick Ratio | 3.49 | 2.60 | 6.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.33 Billion | CN¥ 1.50 Billion | CN¥ 1.71 Billion |
Tonghua Dongbao Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Tonghua Dongbao Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.48 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -5.1% |
| Total Assets | CN¥7.38 Billion |
| Market Capitalization | $1.28 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Tonghua Dongbao Pharmaceutical Co Ltd's assets below their book value (0.17 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Tonghua Dongbao Pharmaceutical Co Ltd's assets decreased by 5.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Tonghua Dongbao Pharmaceutical Co Ltd (1994–2024)
The table below shows the annual total assets of Tonghua Dongbao Pharmaceutical Co Ltd from 1994 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥7.38 Billion | -5.06% |
| 2023-12-31 | CN¥7.77 Billion | +15.13% |
| 2022-12-31 | CN¥6.75 Billion | +3.53% |
| 2021-12-31 | CN¥6.52 Billion | +12.35% |
| 2020-12-31 | CN¥5.80 Billion | +8.47% |
| 2019-12-31 | CN¥5.35 Billion | -2.08% |
| 2018-12-31 | CN¥5.46 Billion | +14.95% |
| 2017-12-31 | CN¥4.75 Billion | +1.66% |
| 2016-12-31 | CN¥4.68 Billion | +23.41% |
| 2015-12-31 | CN¥3.79 Billion | +28.14% |
| 2014-12-31 | CN¥2.96 Billion | +9.72% |
| 2013-12-31 | CN¥2.69 Billion | +13.21% |
| 2012-12-31 | CN¥2.38 Billion | +0.12% |
| 2011-12-31 | CN¥2.38 Billion | +8.74% |
| 2010-12-31 | CN¥2.19 Billion | -2.89% |
| 2009-12-31 | CN¥2.25 Billion | +3.69% |
| 2008-12-31 | CN¥2.17 Billion | -4.31% |
| 2007-12-31 | CN¥2.27 Billion | +15.35% |
| 2006-12-31 | CN¥1.97 Billion | +4.36% |
| 2005-12-31 | CN¥1.88 Billion | +4.36% |
| 2004-12-31 | CN¥1.81 Billion | +0.62% |
| 2003-12-31 | CN¥1.80 Billion | +14.45% |
| 2002-12-31 | CN¥1.57 Billion | +7.69% |
| 2001-12-31 | CN¥1.46 Billion | -0.86% |
| 2000-12-31 | CN¥1.47 Billion | -1.89% |
| 1999-12-31 | CN¥1.50 Billion | +27.04% |
| 1998-12-31 | CN¥1.18 Billion | +34.71% |
| 1997-12-31 | CN¥875.03 Million | +76.45% |
| 1996-12-31 | CN¥495.92 Million | +51.44% |
| 1995-12-31 | CN¥327.48 Million | +22.87% |
| 1994-12-31 | CN¥266.52 Million | -- |